ABOUT
Insight - Innovation - Access - Engagement - Partnering
The one summit which convenes a high level, by-invitation, boutique gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups in digital health, neurotech and A.I. for neurosciences and mental health. Addressing not only opportunities but also the core challenges facing companies and stakeholders. Sharing models, lessons learned, mistakes, solutions, ways forward and best practices. Fostering a unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated summit unlike any other event.
VISION
Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.
Drive transformational connections, discussion and partnering for startups and growth companies.
Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.
Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.
WHY NOW?
From A.I. enabled drug discovery and development, big data, digital biomarkers, Real World Data and trial design, to advanced imaging, companion digital health, cognitive behavioral therapy and connected health, to neuromodulation and V.R., the pace of innovation is unprecedented.
Paradigms are changing, and the potential for positive impact on patient outcomes and quality of life, improved delivery of care, healthcare expenditure, and societal benefit are enormous.
The Neuro Summit is an initiative of Broadreach Global, and is co-organized with the Champalimaud Foundation, with support of Global Innovation Partners.
The first editions in 2022 and 2023 delivered unique, meaningful and high-impact convenings, a who's who of key leaders, innovators and decision-makers. Be a part of it in 2024.
PRESENTING COMPANIES
Join a curated selection of the best, world-class , innovative neuro and mental health companies in NeuroTech, Digital, DeepTech, Data & A.I. with potential to transform healthcare, patient outcomes or markets. Selection is by excellence and potential, not by price tag!
There is no cost to present beyond the regular startup or private company registration fees.
Benefit from:
- Pre-summit guidance and feedback on your deck.
- An on-site dry-run presentation with feedback and coaching from expert mentors.
- A 5 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors and industry: In the plenary session.
- Exclusive post presentation meeting space:
- Meeting Space: A reserved meeting space, prominently placed in the main networking area.
- For 45 minutes in the networking break immediately following the presentation session.
- 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in NeuroTech, Neuro Digital Health, MedTech, DeepTech & A.I.
- Option to add an exclusive company exhibition stand.
Broadreach Summits - What Participants Say
"...Nothing short of incredible. So many brilliant innovators, policymakers, researchers and investors all with the same mission to advance brain health. I was in awe of this groundbreaking growing community and humbled to be invited to take part in it."
Noga Sapir, Founder & CEO -
Reflect Innovation (Israel)
ADVISORY BOARD - announcing the initial members of the 2024 Advisory Board
We are honored to introduce our advisory board: meet them in person at the summit.
 Joe PatonDirector of Neuroscience & Principal Investigator, Champalimaud Foundation |  Ana MaiquesCEO & Co-Founder, Neuroelectrics |  John KrakauerProfessor of the Unknown – Champalimaud Foundation, Professor of Neurology, Neuroscience, and Physical Medicine and Rehabilitation, Director, Brain, Learning, Animation, and Movement - The Johns Hopkins University School of Medicine, Chief Medical Director - Mindmaze |  Sourav KoleManaging Director Life Sciences - Dolby Family Ventures |
|---|---|---|---|
 Beth WolffDirector Digital Health Solutions, Global Business Development & Licensing - Lundbeck |  Pawel SwiebodaFounder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA |  Georgia MitsiPartner, Business & Competitive Strategy - Y Innovations |  Gilad PelegFounding Partner - Neuro1 Capital, Formerly Founding Partner, Corundum Open Innovation & Joy Ventures |
 Martien KasPresident - European College of NeuroPsychopharmacology (ECNP) |  Joachim ScholppGlobal Head Translational Medicine CNS & Emerging Areas, Boehringer Ingelheim, Germany |  Nina PatrickHead of Innovation, DTx Warehouse - Champalimaud Foundation |  Paulo MachadoCEO/Founder - Health Innovation Partners, Angel - What if Ventures, Strategic Advisor - Meadows Mental Health Policy Institute |
 Richard StokvisManaging Director - BOA Healthcare Holdings Limited |  Christian J. SuojanenFounder & CEO - Broadreach Global, Member of the Board - European Brain Foundation (EBF) |
SPEAKERS 2023 - the 2024 lineup of speakers will be announced in June.
Proudly convening leading speakers and stakeholders from across the sector
John KrakauerProfessor of Neurology, Neuroscience, and Physical Medicine & Rehabilitation - Johns Hopkins School of Medicine (Maryland) | Ana MaiquesCEO & Co-Founder - Neuroelectrics (Barcelona) |  Zenna TavaresFounder & Director - Basis Research Institute, Research Scientist - Data Science Institute & Innovation Fellow - Zuckerman Mind Brain Behavior Institute - Columbia University, New York |  Daniela Pimenta da SilvaNeurologist and PhD student - CNS-Campus Neurologico and Faculty of Medicine of the University of Lisbon |
|---|---|---|---|
 Daniel WetmoreSenior Research Scientist - Meta Reality Labs, Director, Clinical & Research Partnerships - CTRL-labs, NY | Joe PatonDirector of Neuroscience & Principal Investigator, Champalimaud Foundation | Joachim ScholppGlobal Head Translational Medicine CNS & Emerging Areas, Boehringer Ingelheim, Germany |  Nick TaptiklisHead of Technology Strategy - Cambridge Cognition (UK) |
Georgia MitsiEnterpreneur in Residence - Emerald BioVentures (Boston) | Pawel SwiebodaFounder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA |  Ariane Tom, PhDFounding Partner - Kaleida Capital (San Diego) |  David Braga MaltaLife Sciences Investor & Entrepreneur - PE Thematic Health, Pictet Bank (Switzerland) |
Paulo MachadoCEO/Founder - Health Innovation Partners, Angel - What if Ventures, Strategic Advisor - Meadows Mental Health Policy Institute |  Amir BozorgzadehCo-Founder & CEO - Virtuleap |  Bruno MontanariPartner - Seroba Life Sciences, Paris |  Beth WolfDirector Digital Health Solutions, Global Corporate Strategy & BD - Lundbeck, Copenhagen |
 Mark TreherneChairperson - Monument Therapeutics. Commercial Scientist, Entrepreneur & Investor. Chairperson of Talisman Therapeutics, Ubiqent, NuVision Biotherapies (UK) |  Julia PrakapovichPartner - Interface Fund (London) |  Dan MannixCEO - Advisor - Brain Health Investor, former CEO - RWC Partners (UK) |  Tiago MarquesSenior Research Scientist - Champalimaud Foundation, Chief Technology Office - HEKA vision, Lisbon |
 Razi SyedHead of Product - Sahha |  Xavier LouisCo-founder & CEO - Five Lives |  Carla Zaldua Aguirre,Co-Founder & CEO - acceXible |  Olivier de SimoneCo-Founder & CEO - Sensae |
 Dr. Laura MurrayClinical Psychologist, CEO/Founder - CETA Global; Senior Scientist - Johns Hopkins Bloomberg School of Public Health, Entrepreneur, Researcher and Clinician (Maryland) |  Joshua HaynesFounder & Managing Partner - Masawa Fund (Berlin) |  Shwen GweeDigital Health & Corporate Innovation Executive, ex BMS Global Head of Digital Strategy, ex-Novartis BIOME & Open Innovation co-founder (Boston) |  Hossein JalaliCofounder & CTO - Virtuleap |
 Naomi GloverCo-Founder/Director - Applied Neuroscience Association (London) |  Hannes KlöpperCEO - HelloBetter Co-Chair - European Policy Task Group of the Digital Therapeutics Alliance |  Marco MohwinckelMental Health Executive & Investor, Chairman – Altibbi, Director - Magnolia Health Advisors (London) |  Xavier Palomer RipollFounder - Amelia Virtual Care |
 Amanda BorgerhoffVice President Client Services - Warman O'Brien |  JP BorgesManaging Partner - JP Borges Abogados, Co-Founder - Exputnik Accelerator (Spain) |  Mick WalshVP Commercial & Business Development - Head Diagnostics (Ireland) |  Hana BesbesInvestor - Heal Capital (Berlin) |
 Jason DictenbergInvestor, Executive, CEO - AccelBio, Chairman - Evergreen Biosciences, Advisory Board Member - Alzheimer's Drug Discovery Foundation, Editor - CellR4 Journal on Regenerative Medicine (New York) | Richard StokvisManaging Director - BOA Healthcare Holdings Limited |  Lorena Muñoz VivasCEO - Effectia Consulting (Spain) |
2OI8RM
WHO'S COMING?
Two days of sustained, interactive discussion, networking and partnering with:
Industry Leaders
Senior industry executives from pharma, digital health, technology & health providers & systems. Heads of therapeutic area, R&D, real world data, clinical development, digital health, scouting, business development & licensing.
Key Opinion Leaders
Key Opinion Leaders from all stakeholder groups at the confluence of neurosciences & mental health with digital, technology, data and A.I.
Founders & CEOs
From startup and growth companies at the confluence of neuroscience and mental health with digital, medtech, imaging, technology, data and A.I.
Government & NGOs
Public agencies, societies, associations & NGOs in brain health, neurology, neurosciences, psychiatry & mental health, patient organizations, economic development, health, research & innovation.
Investors
In CNS, neuroscience and mental health, data, health tech, digital health, A.I. and deeptech.
VC and corporate venture, private equity, family offices, angels & HNW.
Leading Advisors
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.
VENUE
Champalimaud Foundation
Av. Brasília, 1400-038
Lisbon, Portugal
The Champalimaud Foundation carries out research in cutting-edge fields and strives to stimulate discoveries that benefit people, and to promote new standards of knowledge.
It is at the Champalimaud Centre for the Unknown, in Lisbon, that the Foundation develops its activity in the areas of neuroscience and cancer. This is done through both research programmes and the provision of clinical services of excellence. It also has an outreach programme to fight blindness.
To pursue its objectives in achieving significant scientific advances, the Champalimaud Foundation adopts a translational methodology, which establishes a direct link and interdependency between basic research and clinical activity. This is a fundamental part of the Foundation’s methodology.
Ultimately, the Champalimaud Foundation aims to promote the health and well-being of humankind by seeking to actively participate in the search for solutions that can alleviate the burden of disease on societies and individuals.
CO-ORGANIZED WITH
STRATEGIC PARTNERS & SPONSORS
GOLD SPONSOR
STRATEGIC PARTNERS
ASSOCIATION PARTNERS
GET IN TOUCH
Reach us here if you like to
-
Nominate a speaker
-
Apply to present your company or technology
-
Enquire about sponsorship & exhibition opportunities
Be the first to know
Subscribe and be among the first to receive all updates, announcements and invitations.
Please make sure to double check your email address.
SHARE
A Broadreach Global Initiative
Contact us at:
Follow us
